These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18208934)

  • 1. Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms.
    Alexandrino-Silva C; Nadalini Mauá FH; de Andrade AG; de Toledo Ferraz Alves TC
    J Psychopharmacol; 2008 Mar; 22(2):214-6. PubMed ID: 18208934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD; Shults J
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications.
    Vanoli A; Lane C; Harrison C; Steen N; Young A
    J Psychopharmacol; 2008 Jun; 22(4):434-40. PubMed ID: 18635723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
    Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.
    Mbaya P; Alam F; Ashim S; Bennett D
    Hum Psychopharmacol; 2007 Apr; 22(3):129-33. PubMed ID: 17397100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2D6 genotype variation and venlafaxine dosage.
    McAlpine DE; O'Kane DJ; Black JL; Mrazek DA
    Mayo Clin Proc; 2007 Sep; 82(9):1065-8. PubMed ID: 17803873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
    Preskorn SH
    J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lithium and venlafaxine interaction: a case of serotonin syndrome.
    Adan-Manes J; Novalbos J; López-Rodríguez R; Ayuso-Mateos JL; Abad-Santos F
    J Clin Pharm Ther; 2006 Aug; 31(4):397-400. PubMed ID: 16882112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
    Preskorn SH
    J Psychiatr Pract; 2010 May; 16(3):177-82. PubMed ID: 20485106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient.
    Liau CH; Shen WW; Su KP
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):121-2. PubMed ID: 16472373
    [No Abstract]   [Full Text] [Related]  

  • 12. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity.
    Wijnen PA; Limantoro I; Drent M; Bekers O; Kuijpers PM; Koek GH
    Ann Clin Biochem; 2009 Nov; 46(Pt 6):527-30. PubMed ID: 19822698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine withdrawal syndrome.
    Sabljić V; Ružić K; Rakun R
    Psychiatr Danub; 2011 Mar; 23(1):117-9. PubMed ID: 21448114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms.
    Reznik I; Rosen Y; Rosen B
    J Psychopharmacol; 1999; 13(2):193-5. PubMed ID: 10475726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting.
    Bukh JD; Jørgensen MB; Dam H; Plenge P
    Nord J Psychiatry; 2009; 63(4):347-51. PubMed ID: 19347769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
    Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
    Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
    Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
    Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose venlafaxine-induced severe rhabdomyolysis: a case report.
    Huang SS; Yang HY; Lin YC; Chan CH
    Gen Hosp Psychiatry; 2012; 34(4):436.e5-7. PubMed ID: 22459996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders.
    Zimmer B; Kant R; Zeiler D; Brilmyer M
    Int J Psychiatry Med; 1997; 27(4):353-64. PubMed ID: 9565731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.